European prize for mobile vaccination units The Netherlands’ mobile vaccination units (prikbussen) have been selected as a best-practice method for the European project ‘Overcoming Obstacles to Vaccination’.
Number of Lyme disease diagnoses remains high In 2021, the number of Lyme disease diagnoses with a red ring or rash– known as an erythema migrans, or EM – remained as high as in the previous survey in 2017. GPs diagnosed 25,600 patients with a red ring or rash caused by the Lyme bacteria.
Concerns over falling vaccination coverage within National Immunisation Programme The percentage of children vaccinated within the National Immunisation Programme (NIP) has fallen for the second year in a row, according to the 2022 report ‘Vaccination Coverage and Annual Report of the Dutch National Immunisation Programme'. RIVM is concerned about this decline.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
Fewer reports of tick bites in 2022 In 2022, the reported number of tick bites in the Netherlands fell by a third compared to previous years. In order to find a satisfactory explanation for such differences, researchers at WUR and RIVM have initiated a large-scale study via Tekenradar.nl. This will give them more insights into the 1.5 million tick bites in the Netherlands every year.
Safe recycling of textiles possible, but still in its infancy Textiles are produced using chemicals. Although many hazardous chemicals may no longer be used in textile production, they may still be present in donations of old clothing. RIVM has conducted a study into the safety of recycled textiles.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.